Pasithea Therapeutics (KTTA) Free Cash Flow (2021 - 2026)

Pasithea Therapeutics has reported Free Cash Flow for 6 years, with the latest figure at -$4.8 million in Q1 2026.

• Quarterly Free Cash Flow fell 56.66% year-over-year to -$4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$16.9 million (down 33.85% YoY) and the FY2025 annual result came in at -$15.2 million, down 9.25% from the prior year.
• Free Cash Flow improved to -$4.8 million in Q1 2026 per KTTA's latest filing, from -$5.4 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$1.9 million in Q2 2022 and troughed at -$5.4 million in Q4 2025.
• A 5-year average of -$3.5 million and a median of -$3.3 million in 2023 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2022 and 2023: Free Cash Flow plunged 743.68% in 2022, then jumped 30.51% in 2023.
• Over 5 years, Free Cash Flow stood at -$3.3 million in 2022, then declined by 0.49% to -$3.3 million in 2023, then grew by 25.84% to -$2.4 million in 2024, then sank by 120.91% to -$5.4 million in 2025, then increased by 11.3% to -$4.8 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$4.8 million, -$5.4 million, and -$2.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.